title: Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD.
abstract: This article summarises key presentations relevant to the pathophysiology, prevention or treatment of heart failure, from the Heart Failure Society of America annual meeting held in Toronto, Canada. Data from the EnoxiMone in intravenous inOTropE-dependent subjects (EMOTE) study suggest that the oral PDE-3 inhibitor enoximone may be effective for weaning severe heart failure patients from intravenous inotropic therapy. Hawthorn Extract Randomised Blinded Trial in CHF (HERB-CHF) failed to show a benefit of hawthorn extract added to conventional heart failure therapy. A genetic sub-group analysis of the Blocker Evaluation of Survival Trial (BEST) study showed that bucindolol reduced mortality and hospitalisations in patients who were homozygous for the Arg389 variant of the beta(1) adrenoceptor. In the Resynchronisation Hemodynamic Treatment for Heart Failure Management (RHYTHM-ICD) study, patients randomised to cardiac resynchronisation therapy (CRT) showed an improvement in symptoms and functional capacity compared to the control group.
authors.affiliation: Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston-upon-Hull, HU16 5JQ, UK.
authors.forename: Krishna
authors.initials: K
authors.lastname: Lalukota
authors.forename: John G F
authors.initials: JG
authors.lastname: Cleland
authors.forename: Lee
authors.initials: L
authors.lastname: Ingle
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Clark
authors.forename: Alison P
authors.initials: AP
authors.lastname: Coletta
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001120:Arginine; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D027825:Crataegus; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D017335:Enoximone / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D017079:Exercise Tolerance / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D006720:Homozygote; D006801:Humans; D010101:Oxygen Consumption / Q000187:drug effects; D010936:Plant Extracts / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018342:Receptors, Adrenergic, beta-1 / Q000235:genetics; D012955:Societies, Medical; D013318:Stroke Volume / Q000187:drug effects; D016019:Survival Analysis; D017211:Treatment Failure; D016896:Treatment Outcome; D014481:United States
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D002317:Cardiovascular Agents; D004791:Enzyme Inhibitors; D010936:Plant Extracts; D011412:Propanolamines; D018342:Receptors, Adrenergic, beta-1; D001120:Arginine; D017335:Enoximone; C024307:bucindolol; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3